FDA Approves PRALUENT for Rare Pediatric Disease Priority Review Voucher

Summary

The FDA has approved PRALUENT, a drug product manufactured by Sanofi-Aventis U.S. Inc., under a priority review, following a sponsor's redemption of a rare pediatric disease priority review voucher.